MIST Company Profile and Key Details

Short-term trend indicators are mixed aligned (SMA20 -3.4%, SMA50 -11.44%, SMA200 -8.65%). The stock’s 14-day RSI is 39.6 (weak momentum), while the ATR of 0.1 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -43.79% below its high and over 175.02% above its low. Average 10-day trading volume of 2.09 million shares is in line with the 3-month average of 2.26 million, indicating normal recent market interest.

Milestone Pharmaceuticals Inc. has 84.96 million shares outstanding. The public float is 53.46 million shares, elevated short interest at 6.65% of float. This equals 5.65 million shares. The short ratio is 2.24 days. Institutional investors hold 27.79% of the float. Insiders own 2.4%. WONG RODERICK holds 4.32 million shares, RTW INVESTMENTS, LP has 4.32 million shares and Novo Holdings A/S has 2.43 million shares. Over the past six months, insider transactions show net selling. They sold 486.58 thousand shares across 12 transactions.

Milestone Pharmaceuticals Inc. generated EPS of -$0.86 over the past year. Five-year average earnings growth is 28.21%. Wall Street analysts project EPS growth of -6.42% annually over the next five years. The latest quarter delivered EPS of -$0.12. The next quarter is forecast at -$0.16. Next year's EPS is expected at -$26.92. Analyst sentiment is bullish. Analyst rating data shows there are 2 Strong Buy ratings, 3 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $8.00 to $4.00. The high target offers 292.16% upside. The low target suggests 96.08% downside. The mean target is $7.20. This offers 252.94% upside. Milestone Pharmaceuticals Inc. earnings surprise history is a mixed track record. The quarter that ended November 12, 2025, missed forecasts by -29.41%. The prior quarter beat by 11.11%. Over the last six quarters, Apple has recorded several small beats. These include -26.32% in August 08, 2024.

Milestone Pharmaceuticals Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.17. This means the shares are trading above this model’s fair value.

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) closed at $2.04 USD, losing -$0.06 (-2.86%) from the previous close of $2.10. The stock is currently mid-range between its 52-week high and low $0.98 and $3.06. With a market capitalization of about $175.21 million, Milestone Pharmaceuticals Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~0.69). Key stats such as the average daily volume over the past year has been around 2.24 million shares, in line with its 52-week average. Headquartered in Montreal, QC, Milestone Pharmaceuticals Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Joseph G. Oliveto, the company employs approximately 33 people and listed since May 09, 2019. Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines.

Milestone Pharmaceuticals Inc. trades at a P/E ratio of -2.77, slightly below the S&P 500 average, with a price-to-sales ratio of 115.56 and a price-to-book ratio of 4.18 trading at moderately above to book value. The P/FCF stands at -3.64, also above market averages.

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) shares are flat -0.5% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Milestone Pharmaceuticals Inc. trading at a premium to the broader market with a P/E of -2.77. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $18.33, suggesting 798.53% upside. Our AI forecast model points to short-term strength (0.98% over two weeks), a medium-term rise (219.12% over three months), and a longer-term gain (409.8% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Milestone Pharmaceuticals Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 0.98%, with price expected at $2.06 by May 04, 2026, within a range of $1.72 to $2.40 3-Month Outlook: Projected rise of 219.12%, reaching $6.51 by July 17, 2026, with a range of $6.36 to $6.81. 1-Year Outlook: Projected gain of 409.8%, with price at $10.40 by April 20, 2027, within a range of $7.15 to $12.63.